Nurix Therapeutics reported its financial results for the second fiscal quarter ended May 31, 2025. Revenue for the quarter was $44.1 million, a significant increase from $12.1 million in the same period of 2024. This substantial rise was primarily driven by $30 million in license revenue from two Sanofi license extensions and a $5 million clinical milestone achieved under Nurix’s collaboration with Gilead.
Research and development expenses for the quarter increased to $78.1 million, up from $48.9 million in the prior year period. This increase reflects the company's continued acceleration of patient enrollment in the bexobrutideg trial and preparations for initiating pivotal trials. The net loss for the quarter was $43.5 million, or $0.52 per share, which was narrower than the $44.5 million, or $0.71 per share, reported in Q2 2024.
As of May 31, 2025, Nurix held $485.8 million in cash, cash equivalents, and marketable securities. The company highlighted recent achievements, including updated positive data for bexobrutideg at EHA2025 and ICML-18, Sanofi's extension of its STAT6 collaboration, and FDA clearance of the IND for the IRAK4 degrader GS-6791/NX-0479. Nurix is now advancing bexobrutideg into pivotal studies in CLL.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.